Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its attention on lead cancer drug mitazalimab as it prepares for phase 3 trials.

A leading IT industry organisation in the UK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care, saying it is vital not to ...

Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates ...

In the era of digital health transformation, generative AI (GenAI) has emerged as a breakthrough technology in pharmacovigilance, the science dedicated to ensuring drug safety. Pharmacovigilance ...

In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Four years after buying exclusive US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal. Deprexis is an online cognitive ...

Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada – the first international trial of the technology.

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

The successful delivery of CGTs hinges on the development of scalable and resilient supply chains that can meet difficult logistical requirements and temperature controls. Achieving success ...